Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transcenta HoldingHKSE:06628 +7.06%40 Days Inventory is 697.28 as of Dec. 2025, which is 449% above its 10-year median of 126.99. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 639 Biotechnology companies, Transcenta Holding ranks worse than 91.24% on this metric.
The historical rank and industry rank for Transcenta Holding's Days Inventory or its related term are showing as below:
HKSE:06628'
s Days Inventory Range Over the Past 10 Years
Min: 40.2 Med: 126.99 Max: 962.85
Current: 962.85
During the past 7 years, Transcenta Holding's highest Days Inventory was 962.85. The lowest was 40.20. And the median was 126.99.
HKSE:06628's Days Inventory is ranked worse than 91.24% of 639
companies
in the Biotechnology industry
Industry Median: 184.66
vs HKSE:06628: 962.85
Transcenta Holding's Days Inventory
declined
from Dec. 2024 (735.47) to Dec. 2025 (697.28).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Transcenta Holding's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Transcenta Holding's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 3.07.
Transcenta Holding (HKSE:06628) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Transcenta Holding's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Transcenta Holding's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Transcenta Holding Days Inventory Related Terms
Transcenta Holding Days Inventory Historical Data
* Premium members only.
The historical data trend for Transcenta Holding's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06628 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Transcenta Holding's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transcenta Holding Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transcenta Holding's Days Inventory distribution charts can be found below:
* The bar in red indicates where Transcenta Holding's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transcenta Holding (HKSE:06628) has a Days Inventory of 697.28 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Transcenta Holding and its competitors. This is 449% above median its historical median of 126.99. Over the past decade, Transcenta Holding's Days Inventory has ranged from 40.20 to 962.85. According to the industry distribution chart, Transcenta Holding ranks #583 out of 639 companies in the Biotechnology industry, placing it in the top 91.2%.
Is Transcenta Holding's Days Inventory too high?
Transcenta Holding's current Days Inventory of 697.28 is 449% above median its 10-year median of 126.99. Over the past 10 years, this metric has ranged from a low of 40.20 to a high of 962.85. The Biotechnology industry median Days Inventory is 184.66. Transcenta Holding's value of 697.28 is 277.6% above this industry median. Based on the distribution chart, Transcenta Holding ranks #583 out of 639 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transcenta Holding ranks #583 out of 639 companies for Days Inventory. This places Transcenta Holding in the lower half of its industry. The industry median Days Inventory is 184.66. Transcenta Holding's value of 697.28 is 277.6% above this benchmark. Historically, Transcenta Holding's own Days Inventory has ranged from 40.20 to 962.85 over the past decade. While the company's 10-year median is 126.99 vs. the industry median of 184.66, Transcenta Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.66, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transcenta Holding's current Days Inventory of 697.28 is 277.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Transcenta Holding and its competitors. For the Biotechnology industry, the median Days Inventory is 184.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transcenta Holding's current Days Inventory is 697.28, which is 449% above median its own 10-year median of 126.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Days Inventory is 697.28, which is 449% above median its 10-year median of 126.99 and 277.6% above the Biotechnology industry median of 184.66. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Days Inventory is 697.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transcenta Holding (HKSE:06628) Overvalued in 2026?
Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued.
The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Transcenta Holding to be Significantly Overvalued.
Key valuation signals for HKSE:06628:
Days Inventory: 697.28 (449% above median its 10-year median of 126.99)
GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
Industry Position: 277.6% above the Biotechnology median (#583 of 639)
No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score
Get the complete analysis for HKSE:06628
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06628 has been successfully added to your 
